Top holdings
As of March 31, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| INSMED INC | — | $17.03M | 3.04% |
| VAXCYTE INC | — | $16.67M | 2.97% |
| UNIQURE N.V. | — | $15.91M | 2.84% |
| ARGENX SE SPONSORED ADR | — | $14.34M | 2.56% |
| DYNE THERAPEUTICS INC | — | $13.85M | 2.47% |
| DENALI THERAPEUTICS INC | — | $12.76M | 2.28% |
| AXSOME THERAPEUTICS INC | — | $12.46M | 2.22% |
| XENON PHARMACEUTICALS INC | — | $11.78M | 2.10% |
| FULCRUM THERAPEUTICS INC | — | $11.65M | 2.08% |
| TECTONIC THERAPEUTIC INC | — | $11.46M | 2.04% |
Portfolio moves
Dec 31, 2025 → Mar 31, 2026Opened
20
Exited
16
Increased
37
Decreased
24
Unchanged
48
How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| abrdn Healthcare Investors | 75% | — |
| State Street(R) SPDR(R) S&P(R) Biotech ETF · XBI | 29% | 0.35% |
| Franklin Biotechnology Discovery Fund · FBDIX, FTDZX, FRBRX, FBTDX | 29% | 0.67% |
Footnotes
- Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.